Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the Ocular Hypertension Treatment Study

Cornea

Volumn 25, Issue 9, 2006, Pages 1046-1052

  Baratz, Keith H ^a   Nau, Cherie B ^a   Winter, Eric J ^a   McLaren, Jay W ^a   Hodge, David O ^a   Herman, David C ^a   Bourne, William M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Endothelium; Glaucoma; Keratocytes; Medication; Nerves; Toxicity

Indexed keywords

APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFOCAL MICROSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA CELL; CORNEA ENDOTHELIUM; ENDOTHELIUM CELL; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPECULAR MICROSCOPY;

ANTIHYPERTENSIVE AGENTS; CELL COUNT; CORNEA; ENDOTHELIUM, CORNEAL; FEMALE; FIBROBLASTS; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC NERVE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33845366497     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000230499.07273.c5     Document Type: Article

References (49)

1. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
2. Yalvac IS, Gedikoglu G, Karagoz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
3. Shimazaki J, Hanada K, Yagi Y, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v. 0.12% unoprostone. Br J Ophthalmol. 2000;84:1250-1254.
4. Thygesen J, Aaen K, Theodorsen F, et al. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand. 2000;78:37-44.
5. Herreras JM, Pastor JC, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088.
6. Sudesh S, Cohen EJ, Rapuano CJ, et al. Corneal toxicity associated with latanoprost. Arch Ophthalmol. 2004;117:539-540.
7. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12:480-485.
8. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol. 2002;86:418-423.
9. Lass JH, Khosrof SA, Laurence JK, et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998;116:1003-1010.
10. Matsuda M, Ishii Y, Awata T, et al. The effect of long-term topical administration of commercial beta blockers on the rat corneal endothelium. Int Ophthalmol. 1989;13:67-73.
11. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.
12. Egan CA, Hodge DO, McLaren JW, et al. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest Ophthalmol Vis Sci. 1998;39:23-29.
13. Gordon MO, Kass MA, for the Ocular Hypertension Study Group. The Ocular Hypertension Treatment Study. Design and baseline description of the participants. Arch Ophthalmol. 1999;117:573-583.
14. Ohno K, Nelson LR, McLaren JW, et al. Comparison of recording systems and analysis methods in specular microscopy. Cornea. 1999;18:416-423.
15. Patel SV, McLaren JW, Camp JJ, et al. Automated quantification of keratocyte density by using confocal microscopy in vivo. Invest Ophthalmol Vis Sci. 1999;40:32-36.
16. Müller LJ, Marfurt CF, Kruse F, et al. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76:521-542.
17. Calvillo MP, McLaren JW, Hodge DO, et al. Corneal reinnervation after LASIK: Prospective 3-year longitudinal study. Invest Ophthalmol Vis Sci. 2004;45:3991-3996.
18. Patel SV, McLaren JW, Hodge DO, et al. Normal human keratocyte density and corneal thickness measurement by using confocal microscopy in vivo. Invest Ophthalmol Vis Sci. 2001;42:333-339.
19. Patel SV, McLaren JW, Hodge DO, et al. Confocal microscopy in vivo in corneas of long-term contact lens wearers. Invest Ophthalmol Vis Sci. 2002;43:995-1003.
20. Lass JH, Eriksson GL, Osterling L, et al. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol. A double-masked, randomized, one-year study. Ophthalmology. 2001;108:264-271.
21. Giasson CJ, Nguyen TQ, Boisjoly HM, et al. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:144-150.
22. Kaminski S, Hommer A, Koyuncu D, et al. Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility. Acta Ophthalmol Scand. 1998;76:78-79.
23. Beneyto P, Perez TM. Effect of continued treatment with timolol maleate on corneal endothelium: a fluorophotometric study. Cornea. 1998;17:600-603.
24. Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997;38:779-782.
25. Davies MS. Corneal anaesthesia after alcohol injection of the trigeminal sensory root. Br J Ophthalmol. 1970;54:577-586.
26. de Haas EBH. Dessication of cornea and conjunctiva after sensory denervation. Significance of desiccation for pathogenesis of neuroparalytic keratitis. Arch Ophthalmol. 1962;67:79-92.
27. Pannabecker CL. Keratitits neuroparalytica. Corneal lesions following operations for trigemimal neuralgia. Arch Ophthalmol. 1944;32:456-463.
28. Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol. 1979;88:739-743.
29. Calissendorff B. Corneal anesthesia after topical treatment with timolol maleate. A case report. Acta Ophthalmol (Copenh). 1981;59:347-349.
30. Vogel R, Clineschmidt CM, Hoeh H, et al. The effect of timolol, betaxolol and placebo on corneal sensitivity in healthy volunteers. J Ocul Pharmacol. 1990;6:85-90.
31. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on cornea sensitivity. Br J Ophthalmol. 1990;74:409-412.
32. Kozobolis VP, Detorakis ET, Maskaleris G, et al. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops. Am J Ophthalmol. 2005;139:742-743.
33. de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221-224.
34. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602-604.
35. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. Cornea. 2003;22:709-715.
36. Ishibashi T, Norihiko Y, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486-490.
37. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556-563.
38. Pisella P-J, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360-1368.
39. Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101:454-460.
40. O'Brien WJ, DeCarlo JD, Stern M, et al. Effects of Timoptic on corneal reepithelialization. Arch Ophthalmol. 1982;100:1331-1333.
41. Nork TM, Holly FJ, Hayes J, et al. Timolol inhibits corneal epithelial wound healing in rabbits and monkeys. Arch Ophthalmol. 1984;102:1224-1228.
42. Haruta Y, Ohashi Y, Matsuda S. Corneal epithelial deficiency induced by the use of beta-blocker eye drops. Eur J Ophthalmol. 1997;7:334-339.
43. Segawa K, Nagai T, Tanaka N, et al. Effects of three beta-blocker eye drops on the rabbit cornea: an electron microscope study. Clin Ther. 1986;8:263-268.
44. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531-536.
45. Sigelman S, Friedenwald JS. Mitotic and wound-healing activities of the corneal epithelium. Effect of sensory denervation. Arch Ophthalmol. 1954;52:46-51.
46. Alper MG. The anesthetic eye: an investigation of changes in the anterior ocular segment of the monkey caused by interrupting the trigeminal nerve at various levels along its course. Trans Am Ophthalmol Soc. 1975;73:323-365.
47. Herman DC, Hodge DO, Bourne WM. Changes in corneal thickness in patients with treated and untreated ocular hypertension. Cornea. 25:639-643.
48. Patel DV, McGhee CN. Mapping of the normal human corneal sub-basal nerve plexus by in vivo laser scanning confocal microscopy. Invest Ophthalmol Vis Sci. 2005;46:4485-4488.
49. Simo Mannion L, Tromans C, O'Donnell C. An evaluation of corneal nerve morphology and function in moderate keratoconus. Cont Lens Anterior Eye. 2005;8:185-192.